CN Patent

CN110382467A — 结晶药物产品的制备

Assigned to Orlean Co · Expires 2019-10-25 · 7y expired

What this patent protects

本发明涉及N‑((S)‑1‑(3‑(3‑氯‑4‑氰基苯基)‑1H‑吡唑‑1‑基)‑丙烷‑2‑基)‑5‑(1‑羟基乙基)‑1H‑吡唑‑3‑甲酰胺(I)的结晶颗粒，其具有在约8至约16m 2 /g、优选约10至约15m 2 /g的范围内的比表面积(SSA)，和制备所述颗粒的方法。化合物(I)是强效的雄激素受体(AR)调节剂，其可用作药物、例如治疗前列腺癌的药物。

USPTO Abstract

本发明涉及N‑((S)‑1‑(3‑(3‑氯‑4‑氰基苯基)‑1H‑吡唑‑1‑基)‑丙烷‑2‑基)‑5‑(1‑羟基乙基)‑1H‑吡唑‑3‑甲酰胺(I)的结晶颗粒，其具有在约8至约16m 2 /g、优选约10至约15m 2 /g的范围内的比表面积(SSA)，和制备所述颗粒的方法。化合物(I)是强效的雄激素受体(AR)调节剂，其可用作药物、例如治疗前列腺癌的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN110382467A
Jurisdiction
CN
Classification
—
Expires
2019-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Orlean Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.